drugset / Trial / NCT00852189
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of EC0489 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.
Timeline
- Start
- 2009-04
- Primary completion
- 2011-12
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EC0489 | Unknown | 1 mg/m2 | Intravenous |
| Subject | EC0489 | Unknown | 4.2 mg/m2 | Intravenous |
| Background | EC20 | Diagnostic / imaging agent | 740 mbq | Intravenous |
| Background | EC20 | Diagnostic / imaging agent | 925 mbq | Intravenous |